ERIC BOYUM: Open Payments
NPI 1093034266 · FESTUS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$472 in 21 payments from 9 companies in 2025. Trend: 2023 $731 · 2024 $998 · 2025 $472
Food & beverage: $472
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 6 | $114 |
| Otsuka America Pharmaceutical, Inc. | 2 | $112 |
| Janssen Pharmaceuticals, Inc | 3 | $56 |
| Lundbeck LLC | 3 | $54 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| Alkermes, Inc. | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
Products named: INGREZZA, ABILIFY MAINTENA, INVEGA SUSTENNA, REXULTI, AUSTEDO XR, CAPLYTA, Qelbree, ARISTADA.
Industry payments across MO — which companies pay providers there.
